Cancer Genetics Expands Access to Proprietary Diagnostics Through Agreement with Harvard Pilgrim

(CGI; Morrisville, NC, USA) and Harvard Pilgrim Healthcare (Hartford, CT; USA), a health care network covering over one million people throughout Massachusetts, Connecticut, and Maine, CGI will offer its cancer diagnostic services to individuals covered under Harvard Pilgrim plans.

Harvard Pilgrim's extensive provider network includes over 135 hospitals and 28,000 clinicians, among them physicians who practice in a variety of settings, including individual practices, small medical groups, and large multi-specialty groups. As part of the agreement, the Harvard Pilgrim’s network will have access to the full range of oncology-focused proprietary tests offered by CGI.

Working with provider networks is central to CGI's multipart access and reimbursement strategy. By establishing relationships with leading payers and insurance companies, CGI plans to expand access to and reimbursement for its leading-edge genomic tests to help providers appropriately manage and personalize treatment.

Cancer Genetics is an emerging leader in DNA-based cancer diagnostics, with tests that target difficult-to-diagnose hematological, urogenital, and HPV-associated cancers, designed to guide prognosis and treatment. Harvard Pilgrim's innovative approach to healthcare and collaboration with top institutions makes it a natural partner for Cancer Genetics.

"Cancer Genetics is very pleased to announce this relationship with Harvard Pilgrim Health Care. HPHC is one of the most respected health plan organizations in New England and is widely regarded for health care innovation, exceptional clinical quality and member satisfaction," said Randy Goodman, PhD, director of Reimbursement and Clinical Revenue Cycle Management, Cancer Genetics, "This agreement not only provides us with the opportunity to deliver services to a larger number of patients, but also allows us to work jointly with HPHC to help transform cancer patient management, increase treatment efficacy and reduce healthcare costs."

Related Links:
Cancer Genetics
Harvard Pilgrim Health Care